Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Accenture
Express Scripts
Merck
Johnson and Johnson
Farmers Insurance
QuintilesIMS
Queensland Health
Julphar
Fish and Richardson

Generated: May 25, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 020747

« Back to Dashboard

NDA 020747 describes ACTIQ, which is a drug marketed by Cephalon and is included in one NDA. It is available from four suppliers. Additional details are available on the ACTIQ profile page.

The generic ingredient in ACTIQ is fentanyl citrate. There are thirty-one drug master file entries for this compound. Fifteen suppliers are listed for this compound. Additional details are available on the fentanyl citrate profile page.
Summary for 020747
Tradename:ACTIQ
Applicant:Cephalon
Ingredient:fentanyl citrate
Patents:0
Therapeutic Class:Analgesics
Formulation / Manufacturing:see details
Pharmacology for NDA: 020747
Mechanism of ActionFull Opioid Agonists
Suppliers and Packaging for NDA: 020747
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
ACTIQ fentanyl citrate TROCHE/LOZENGE;TRANSMUCOSAL 020747 NDA AUTHORIZED GENERIC Teva Pharmaceuticals USA, Inc. 0093-7865 N 0093-7865-65
ACTIQ fentanyl citrate TROCHE/LOZENGE;TRANSMUCOSAL 020747 NDA AUTHORIZED GENERIC Teva Pharmaceuticals USA, Inc. 0093-7866 N 0093-7866-65

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:TROCHE/LOZENGE;TRANSMUCOSALStrengthEQ 0.2MG BASE
Approval Date:Nov 4, 1998TE:ABRLD:Yes

Profile for product number 002

Active Rx/OTC/Discontinued:RXDosage:TROCHE/LOZENGE;TRANSMUCOSALStrengthEQ 0.4MG BASE
Approval Date:Nov 4, 1998TE:ABRLD:Yes

Profile for product number 003

Active Rx/OTC/Discontinued:RXDosage:TROCHE/LOZENGE;TRANSMUCOSALStrengthEQ 0.6MG BASE
Approval Date:Nov 4, 1998TE:ABRLD:Yes

Expired US Patents for NDA 020747

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Cephalon ACTIQ fentanyl citrate TROCHE/LOZENGE;TRANSMUCOSAL 020747-003 Nov 4, 1998 ➤ Try a Free Trial ➤ Try a Free Trial
Cephalon ACTIQ fentanyl citrate TROCHE/LOZENGE;TRANSMUCOSAL 020747-001 Nov 4, 1998 ➤ Try a Free Trial ➤ Try a Free Trial
Cephalon ACTIQ fentanyl citrate TROCHE/LOZENGE;TRANSMUCOSAL 020747-001 Nov 4, 1998 ➤ Try a Free Trial ➤ Try a Free Trial
Cephalon ACTIQ fentanyl citrate TROCHE/LOZENGE;TRANSMUCOSAL 020747-006 Nov 4, 1998 ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Fish and Richardson
Johnson and Johnson
Colorcon
UBS
Merck
Cantor Fitzgerald
Dow
QuintilesIMS
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.